ProQR Therapeutics, a dutch biotech developing mRNA treatments for cystic fibrosis, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.
The Leiden, Netherlands-based company, which was founded in 2012, plans to list on the NASDAQ but has not selected a ticker. ProQR Therapeutics initially filed confidentially on July 11, 2014. Leerink Partners and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
